Medtronic, Inc: Should You Buy This Dividend Aristocrat?

See why Medtronic might be able to increase dividends for another 25 years.

May 6, 2014 at 2:30PM

Investors looking for reliable cash returns should be well familiarized with dividend aristocrats like Medtronic (NYSE:MDT). Members of this elite class have successfully increased their dividends every year for at least 25 years.

This giant medical device manufacturer enjoys resistance to economic downturns, and highly effective research and development programs. Medtronic has steadily raised distributions at an impressive rate without over-extending itself. Here's a closer look at that dividend, and why Medtronic might remain an aristocrat for years to come.

MDT Dividend Chart

MDT Dividend data by YCharts

Over the past decade Medtronic has increased its dividend at a CAGR of 12.8%. During the past three years it's done so using less than one third of net income. While it might be nice to see more of those earnings in your pocket, it's also good to know the company is finding opportunities for investing that money.

Nimble innovator
Medtronic may be the largest company solely focused on medical devices, but it is hardly a lumbering giant. It's R&D budget towers over competitors, but it also spends a lower percentage of its revenue on R&D.

MDT Research and Development Expense (TTM) Chart

MDT Research and Development Expense (TTM) data by YCharts

One reason for Medtronic's ability to squeeze more sales from its R&D department comes from being first to market with innovative products. The company launched the first MRI-safe pacemaker -- the Revo MRI SureScan pacing system -- more than three years ago. Last month it moved beyond pacemakers when the first of 275 patients received MRI-safe cardioverter-defibrillator implants as part of a pivotal trial for FDA approval.

The competition is well behind. St. Jude Medical (NYSE:STJ) began a study for its Accent MRI-safe pacemaker about one year after Medtronic began selling the Revo in the US. Topline results from the trial should be available soon, and complete results are expected this December. Boston Scientific (NYSE:BSX) won EU approval for its MRI-safe pacemaker last July, but hasn't even applied in the US yet. The company began trials with its ImageReady pacing system just over a year ago.

The latest legal battle
The benefits of being quick to market don't end with MRI-safe pacemakers. The patent infringement feud between Edwards Lifesciences (NYSE:EW) and Medtronic, sparked in part because Medtronic successfully brought its CoreValve system to market months earlier than expected, took an unusual turn recently.


Sapien XT image source: Edwards Lifesciences

Last month a U.S. District Court issued a preliminary injunction against Medtronic's CoreValve system stating it infringed on patents for Edward's Sapien transcatheter heart valve. Both of these devices replace faulty aortic valves in patients unable to undergo open heart surgery. 

The trouble is, CoreValve may be suitable for more patients than Edwards' Sapien device, meaning that a ban on the device could prevent some patients from receiving this particular type of treatment. As Medtronic notes in court documents, "if the injunction were permitted to go into effect, treatable patients may unnecessarily die" because of lack of access to the CoreValve system. Perhaps due to this safety concern, a federal appeals court delayed the injunction a week after it was filed.

Final take
The CoreValve infringement suits were hardly a surprise, and the latest injunction isn't the first. You can argue back and forth about the "willful" nature of the infringement. The thing we can be sure of is Medtronic's ability to quickly bring a product to the market and then keep it there.

Medtronic is also using that hefty R&D budget to develop innovative products years ahead of the competition. High switching costs for surgeons give the company a degree of pricing power, and that's a formula for long-term dividend growth that you can depend on.

More top dividend stocks for the next decade
The smartest investors know that dividend stocks simply crush their non-dividend paying counterparts over the long term. That's beyond dispute. They also know that a well-constructed dividend portfolio creates wealth steadily, while still allowing you to sleep like a baby. Knowing how valuable such a portfolio might be, our top analysts put together a report on a group of high-yielding stocks that should be in any income investor's portfolio. To see our free report on these stocks, just click here now.

Cory Renauer owns shares of Medtronic. The Motley Fool recommends Johnson & Johnson. The Motley Fool owns shares of General Electric Company, Johnson & Johnson, and Medtronic. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

1 Key Step to Get Rich

Our mission at The Motley Fool is to help the world invest better. Whether that’s helping people overcome their fear of stocks all the way to offering clear and successful guidance on complicated-sounding options trades, we can help.

Feb 1, 2016 at 4:54PM

To be perfectly clear, this is not a get-rich action that my Foolish colleagues and I came up with. But we wouldn't argue with the approach.

A 2015 Business Insider article titled, "11 websites to bookmark if you want to get rich" rated The Motley Fool as the #1 place online to get smarter about investing.

"The Motley Fool aims to build a strong investment community, which it does by providing a variety of resources: the website, books, a newspaper column, a radio [show], and [newsletters]," wrote (the clearly insightful and talented) money reporter Kathleen Elkins. "This site has something for every type of investor, from basic lessons for beginners to investing commentary on mutual funds, stock sectors, and value for the more advanced."

Our mission at The Motley Fool is to help the world invest better, so it's nice to receive that kind of recognition. It lets us know we're doing our job.

Whether that's helping the entirely uninitiated overcome their fear of stocks all the way to offering clear and successful guidance on complicated-sounding options trades, we want to provide our readers with a boost to the next step on their journey to financial independence.

Articles and beyond

As Business Insider wrote, there are a number of resources available from the Fool for investors of all levels and styles.

In addition to the dozens of free articles we publish every day on our website, I want to highlight two must-see spots in your tour of

For the beginning investor

Investing can seem like a Big Deal to those who have yet to buy their first stock. Many investment professionals try to infuse the conversation with jargon in order to deter individual investors from tackling it on their own (and to justify their often sky-high fees).

But the individual investor can beat the market. The real secret to investing is that it doesn't take tons of money, endless hours, or super-secret formulas that only experts possess.

That's why we created a best-selling guide that walks investors-to-be through everything they need to know to get started. And because we're so dedicated to our mission, we've made that available for free.

If you're just starting out (or want to help out someone who is), go to, drop in your email address, and you'll be able to instantly access the quick-read guide ... for free.

For the listener

Whether it's on the stationary exercise bike or during my daily commute, I spend a lot of time going nowhere. But I've found a way to make that time benefit me.

The Motley Fool offers five podcasts that I refer to as "binge-worthy financial information."

Motley Fool Money features a team of our analysts discussing the week's top business and investing stories, interviews, and an inside look at the stocks on our radar. It's also featured on several dozen radio stations across the country.

The hosts of Motley Fool Answers challenge the conventional wisdom on life's biggest financial issues to reveal what you really need to know to make smart money moves.

David Gardner, co-founder of The Motley Fool, is among the most respected and trusted sources on investing. And he's the host of Rule Breaker Investing, in which he shares his insights into today's most innovative and disruptive companies ... and how to profit from them.

Market Foolery is our daily look at stocks in the news, as well as the top business and investing stories.

And Industry Focus offers a deeper dive into a specific industry and the stories making headlines. Healthcare, technology, energy, consumer goods, and other industries take turns in the spotlight.

They're all informative, entertaining, and eminently listenable ... and I don't say that simply because the hosts all sit within a Nerf-gun shot of my desk. Rule Breaker Investing and Answers contain timeless advice, so you might want to go back to the beginning with those. The other three take their cues from the market, so you'll want to listen to the most recent first. All are available at

But wait, there's more

The book and the podcasts – both free ... both awesome – also come with an ongoing benefit. If you download the book, or if you enter your email address in the magical box at the podcasts page, you'll get ongoing market coverage sent straight to your inbox.

Investor Insights is valuable and enjoyable coverage of everything from macroeconomic events to investing strategies to our analyst's travels around the world to find the next big thing. Also free.

Get the book. Listen to a podcast. Sign up for Investor Insights. I'm not saying that any of those things will make you rich ... but Business Insider seems to think so.

Compare Brokers